Hi helen,

Happy New Year! We've turned the page on 2024 and 2025 is here. Time doesn't stop, but neither do we. Pfizer continues to strive to make breakthroughs that change patients' lives, and we'll continue to share them in this newsletter. In fact, we're kicking off the new year with a new innovation.

Artificial intelligence (AI) was everywhere last year and it's going to play an even bigger role in 2025 and beyond - including in healthcare. We're excited to share an AI innovation in cardiology, where we are advancing AI in healthcare by supporting cutting-edge initiatives to accelerate identification of “at-risk” patients. Learn more in this month's featured article.

Every year, Pfizer holds a DEI summit in an effort to bring colleagues together to discuss important topics around diversity, equity, and inclusion. 2024's summit focused on inclusion and connection, and we've shared a recap of the inspiring event. Check it out.

Speaking of inclusion, those suffering from inflammatory bowel disease (IBD), a group of chronic conditions that include Crohn’s disease (CD) and ulcerative colitis (UC), often face more than just health symptoms. Many patients also struggle with barriers to care and diagnosis delays due to systemic healthcare inequities. Read this month's article to learn how we're addressing them.

Our work to outdo cancer continues in 2025, and in December Pfizer attended the San Antonio Breast Cancer Symposium (SABCS) and presented new findings from real-world studies regarding the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. Such real-world evidence is an essential piece of the research puzzle, and we explain why.

As always, we've also shared highlights from Pfizer's social media activity with our December round-up. CEO Albert Bourla looks back at 2024 and ahead to 2025, our Chief Digitial and Technology Officer shares highlights from Pfizer's AI festival, we have new episodes of our "What's in My Lab" and "Specialty Voices of Innovation" video series, and more.

Thanks for reading! 

Harnessing the Power of AI to Detect ATTR-CM

Patients at-risk for rare heart diseases may previously have gone unnoticed with routine screening methods. To help tackle this challenge, Pfizer is helping bring AI into the ATTR-CM space, by supporting innovators in the field. Through embracing AI advances, we hope to help physicians proactively detect at-risk individuals earlier, paving the way for improved health outcomes for patients.

LEARN HOW AI IS HELPING IDENTIFY AT-RISK PATIENTS

Pfizer’s Annual DEI Summit Focuses on Inclusion and Connection

Last fall, Pfizer held our annual all-company DEI summit, which was created years ago in an effort to bring colleagues together to discuss important topics around diversity, equity, and inclusion. Learn more.

Why Real-World Learnings Matter for People with Breast Cancer

In December, Pfizer presented new findings from real-world studies at the San Antonio Breast Cancer Symposium (SABCS), a scientific conference which highlights the latest research in breast cancer. Read about our latest research.

Pfizer Works to Address Inequities in IBD Care

Pfizer is working to overcome the critical care gaps that exist for diverse communities in the IBD space by helping gastroenterologists identify these disparities and recognize how implicit bias may impact disease treatment. Get more details.

Pfizer on Social Media - December Round-up

Stay abreast of the ways Pfizer is breaking through the noise with this monthly recap of our thought leaders’ most thought-provoking posts and our activity across social media.

This content is intended only for a US audience. You're receiving this email because you previously signed up for the Pfizer, Get Healthy Stay Healthy, or Breakthroughs newsletter.

To subscribe to specific topics or content types or to receive automated alerts of newly published content from Pfizer.com, visit Pfizer's Subscription Center.

If you no longer wish to receive professional marketing email communications from Pfizer, unsubscribe here.

Please do not reply as this is an unattended email box.

Pfizer Inc.

66 Hudson Boulevard

New York, NY 10001